newsfilter
← Latest News
GlobeNewswire·

Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results

Phase 1/2 TCR-T Library trial targeting KRAS, TP53 and EGFR mutations across six solid tumor indications; first patient consented and is expected to dose in 2Q 2022 Extended CRADA with the National Cancer Institute focused on evaluating Alaunos' TCR-T